Stay updated on ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.

Latest updates to the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page shows a minor site revision from v3.4.0 to v3.4.1; no changes to study content or navigation are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page shows a new revision tag 'Revision: v3.3.4' replacing the previous 'Revision: v3.3.3', a minor metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedLocations information was updated: a new Locations section lists Florida, Minnesota, Ohio, and South Carolina, with the previous state entries removed; the HHS Vulnerability Disclosure link was also removed.SummaryDifference0.5%

- Check75 days agoChange DetectedPubMed publications description was updated to indicate automatic filling from PubMed, and a revision note shows version v3.3.2.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page no longer displays the government funding lapse notice at the top, and the rest of the study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check104 days agoChange DetectedThe two screenshots show layout and visual adjustments to the Study Details page; core study information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.